Royalty Pharma Pens $500M Royalty Agreement With Ferring Pharmaceuticals For New Intravesical Gene Therapy Adstiladrin® (nadofaragene Firadenovec-vncg)
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring's Adstiladrin for up to $500 million, comprised of an upfront payment of $300 million and a $200 million milestone payment. The milestone payment is contingent on certain manufacturing goals expected to be achieved in 2025. Royalty Pharma is acquiring a 5.1% royalty on net sales of Adstiladrin in the US, which will increase to 8.0% upon payment of the manufacturing-related milestone.
August 24, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Royalty Pharma's acquisition of a synthetic royalty on Ferring's Adstiladrin could provide a significant revenue stream, contingent on the achievement of certain manufacturing goals.
The acquisition of a synthetic royalty on Ferring's Adstiladrin provides Royalty Pharma with a potential significant revenue stream. The deal's structure, which includes a milestone payment contingent on manufacturing goals, indicates a potential increase in revenues if these goals are met. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100